Detalle Publicación

HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples
Autores: Loi, E.; Zavattari, C.; Tommasi, A.; Moi, L.; Canale, M.; Po, A.; Sabato, C.; Vega-Benedetti, A. F.; Ziranu, P.; Puzzoni, M.; Lai, E.; Faloppi, L.; Rullán, M.; Carrascosa, J.; Amat, I.; Urman, J. M.; Arechederra Calderon, Maria; Berasain Lasarte, María del Carmen; Ferretti, E.; Casadei-Gardini, A.; Ávila Zaragoza, Matías Antonio; Alonso, S. (Autor de correspondencia); Scartozzi, M.; Zavattari, P. (Autor de correspondencia)
Título de la revista: BRITISH JOURNAL OF CANCER
ISSN: 0007-0920
Volumen: 126
Número: 12
Páginas: 1783 - 1794
Fecha de publicación: 2022
Lugar: WOS
Background Biliary tract cancers (BTC) are rare but highly aggressive tumours with poor prognosis, usually detected at advanced stages. Herein, we aimed at identifying BTC-specific DNA methylation alterations. Methods Study design included statistical power and sample size estimation. A genome-wide methylation study of an explorative cohort (50 BTC and ten matched non-tumoral tissue samples) has been performed. BTC-specific altered CpG islands were validated in over 180 samples (174 BTCs and 13 non-tumoral controls). The final biomarkers, selected by a machine-learning approach, were validated in independent tissue (18 BTCs, 14 matched non-tumoral samples) and bile (24 BTCs, five non-tumoral samples) replication series, using droplet digital PCR. Results We identified and successfully validated BTC-specific DNA methylation alterations in over 200 BTC samples. The two-biomarker panel, selected by an in-house algorithm, showed an AUC > 0.97. The best-performing biomarker (chr2:176993479-176995557), associated with HOXD8, a pivotal gene in cancer-related pathways, achieved 100% sensitivity and specificity in a new series of tissue and bile samples. Conclusions We identified a novel fully efficient BTC biomarker, associated with HOXD8 gene, detectable both in tissue and bile by a standardised assay ready-to-use in clinical trials also including samples from non-invasive matrices.